Raising Health

Daisy Wolf speaks with Dr. Andrew Huberman, professor of neurobiology and ophthalmology at Stanford University and host of the Huberman Lab podcast. They discuss how the pandemic sparked a consumer health revolution, the emerging peptide and GLP landscape, what the science actually says about focus drugs, and the neurotechnologies Huberman believes will let us write to our own biology within the next five years. Resources: Follow Andrew Huberman on X: https://twitter.com/hubermanlab Follow Daisy Wolf on X: https://twitter.com/daisydwolf Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends! a16z and its affiliates may maintain investments in the companies discussed. Hosted by Simplecast, an AdsWizz company.

a16z Partners Daisy Wolf and Eva Steinman talk with Zach Cohen and Raymond Wang, cofounders of Ease Health, a company building an AI operating system for behavioral health that combines CRM, EHR, and revenue cycle management into a single platform. They discuss why behavioral health software has lagged behind, what it means to build AI native versus AI integrated, and why Zach left his job as an investor at a16z to go build in this space. They also cover how Ease plans to replace the dozen software vendors most practices rely on today. Resources: Follow Daisy Wolf on X: https://x.com/daisydwolf Follow Eva Steinman on LinkedIn: https://www.linkedin.com/in/eva-steinman/ Follow Zach Cohen on X: https://x.com/zachcohen25 Follow Raymond Wang on LinkedIn: https://www.linkedin.com/in/arrays/ Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends! a16z and its affiliates may maintain investments in the companies discussed. Hosted by Simplecast, an AdsWizz company.

At the Oliver Wyman Health Innovation Summit 2025, Julie Yoo, General Partner at a16z Bio + Health, makes the case that healthcare is uniquely positioned to benefit from AI more than any other industry. She argues that healthcare's historical underinvestment in technology is now an asset, enabling the industry to leapfrog directly to AI-native models of care delivery with unprecedented speed and scale. Resources: Follow Julie Yoo on X: https://x.com/julesyoo Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends! a16z and its affiliates may maintain investments in the companies discussed. Hosted by Simplecast, an AdsWizz company.

a16z general partner Julie Yoo talks with Nikhil Buduma, CEO and cofounder of Ambience Healthcare, to discuss how AI is transforming clinical workflows. They cover the early days of deep learning, why Ambience started by running a medical practice before building a platform company, and what it takes to achieve high clinician adoption rates at major academic medical centers. They also dig into the challenge of building products when AI capabilities change every few months, the real ROI that's finally converting CFOs, and why this might be the moment to reimagine the legacy EHR stack. Resources: Follow Nikhil Buduma on X: https://twitter.com/nkbuduma Follow Julie Yoo on X: https://twitter.com/julesyoo Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends! a16z and its affiliates may maintain investments in the companies discussed. For more details please see http://a16z.com/disclosures Hosted by Simplecast, an AdsWizz company.

a16z investors Daisy Wolf and Eva Steinman talk with Bobby Samuels, cofounder and CEO of Protege. They discuss the myth that we've run out of data for AI, how Protege connects healthcare systems and other data holders with the major AI labs, and why real-world data beats synthetic data for training models. Bobby also covers the growing demand for eval datasets, expanding beyond healthcare into video and audio, and what he's seeing from the biggest AI companies as they race to acquire training data. Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends! a16z and its affiliates may maintain investments in the companies discussed. Hosted by Simplecast, an AdsWizz company.

Recently, a16z Bio + Health general partner Julie Yoo spoke with Nikita Singareddy, cofounder of Fortuna, and Florian Otto, cofounder of Cedar. They talked about why healthcare affordability is reaching a breaking point, how AI voice agents are transforming patient financial experiences, and what it will take to leapfrog decades of administrative burden in Medicaid—from 30-page paper applications to legacy technology systems built in the 1990s to the real opportunity for giving every American a "five-star healthcare experience." Resources: Follow Julie Yoo on X: https://twitter.com/julesyoo Follow Nikita Singareddy on X: https://twitter.com/singareddynm Check out Fortuna: https://www.fortunahealth.com/ Follow Florian Otto on X: https://twitter.com/flottobrasil Check out Cedar: https://www.cedar.com/ Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends! a16z and its affiliates may maintain investments in the companies discussed. Hosted by Simplecast, an AdsWizz company.

Out-of-Pocket is a healthcare education company founded by Nikhil Krishnan that helps people understand how healthcare works and how to navigate it in practice. In this episode, a16z investing partner Jay Rughani and Nikhil discuss why health insurance is losing its role as the default way people access care. They explain how rising costs are pushing more consumers to pay out of pocket for diagnostics, preventive care, and navigation. The conversation also looks at what this shift means for startups, AI-powered tools, regulation, and access as healthcare continues to move beyond insurance. Resources: Follow Jay Rughani on X: https://twitter.com/JayRughani Follow Nikhil Krishnan on X: https://twitter.com/nikillinit Read Out of Pocket’s 2026 Predictions: https://www.outofpocket.health/p/out-of-pockets-2026-predictions Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends! a16z and its affiliates may maintain investments in the companies discussed. For more details, please see http://a16z.com/disclosures Hosted by Simplecast, an AdsWizz company.

Cofounders Jeremy Wohlwend and Gabriele Corso join the a16z podcast to discuss the launch of Boltz, a public benefit company building AI infrastructure for molecular biology. The conversation explains how breakthroughs following AlphaFold moved the field beyond protein structure prediction into modeling biomolecular interactions and binding strength, why open-source Boltz models saw rapid adoption across pharma and biotech, and how that work is now being productized. They outline the launch of Boltz Lab, a platform that brings protein and small-molecule design agents into scientist workflows, Boltz’s decision to operate as an infrastructure company rather than a therapeutics company, and how AI could reduce early drug discovery bottlenecks by improving molecular design and speeding iteration between computation and the lab. Resources: Follow Gabriele on X: https://twitter.com/GabriCorso Follow Jeremy on X: https://twitter.com/jeremyWohlwend Follow Jorge X: https://twitter.com/jorgecondebio Follow Zak on X: https://twitter.com/zakdoric Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends! a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures. Hosted by Simplecast, an AdsWizz company.

In this episode, a16z GP Julie Yoo sits down with Peter McCanna, CEO of Baylor Scott & White Health, to break down how one of America's largest health systems is transforming from a supply-driven "walled castle" to a customer-centric ecosystem, and how it's achieving a 10% operating margin while most hospitals struggle to stay in the black. They get into why helping his father navigate healthcare convinced Pete the entire system is fundamentally broken, what differentiates academic medical centers from community health systems, and why traditional hospital economics root out essential services like behavioral health. Peter also explains how ambient AI reduced physician burnout rates by 70%, why AI will eventually replace any job involving human-screen interaction, and what he looks for in startup partnerships beyond just TAM and business fundamentals. Resources: Follow Peter on LinkedIn: https://www.linkedin.com/in/peter-mccanna-784619104 Follow Julie on X: @julesyoo Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends! a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures. Hosted by Simplecast, an AdsWizz company.

A labor and delivery nurse who ran Senate healthcare policy now manages $1.7 trillion in federal health spending—and she runs her team like a startup. Steph Carlton, Chief of Staff and Deputy Administrator at CMS, reveals the OKRs driving Medicare and Medicaid, why they're killing social determinants funding while building consumer health apps at scale, and how real-time provider data could collapse the 18-month lag between care delivery and payment. The team mixing founders with policy veterans is rewriting quality measures around VO2 max and app engagement, not just disease management—because preventing illness years before it happens might finally be worth more than treating it after. Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends! a16z and its affiliates may maintain investments in the companies discussed. For more details please see http://a16z.com/disclosures Hosted by Simplecast, an AdsWizz company.

Drug discovery has doubled the flow of candidates, but approvals remain roughly flat. The constraint is development, not discovery. In this episode, a16z General Partner, Jorge Conde talks with Formation Bio cofounder and CEO Ben Liu about building a modern pharma company around clinical execution. They discuss Formation Bio’s hub-and-spoke model for acquiring and advancing assets, how AI compresses trial timelines and costs, picking winners, regulatory strategy, and what it would take to move from about 50 approvals a year to many more. They also touch on global competition and why clinical proof still drives value in today’s market.\ Timecodes: 0:00 Introduction 0:38 Why Formation Bio? Origins and Mission 1:12 The Real Bottleneck: Clinical Development 4:56 Formation Bio’s Business Model 7:50 Picking Winners: The Art and Science of Drug Selection 11:54 First-in-Class vs. Best-in-Class Strategies 14:04 Overcoming Regulatory and Market Challenges 17:26 The Stakes: Can We Approve More Drugs? 19:07 How Formation Bio Cuts Cost and Time 21:43 AI’s Role in Drug Development 25:10 The Future: From 50 to 500 Drug Approvals? 35:18 Global Competition: The Rise of China 39:28 The Path Forward: Data, Regulation, and Access 41:47 Conclusion: Realizing the AI Revolution in Pharma Resources: Find Ben on X: https://x.com/BenjamineYLiu Find Jorge on X: https://x.com/JorgeCondeBio Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends! a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures. Hosted by Simplecast, an AdsWizz company.

Josh Weiner left Meta to return to CVS Health with two painful realizations: consumers don't manage their health—they expect it, and the healthcare market fundamentally violates every principle of economics. In this conversation with a16z's Julie Yoo, the CVS Senior VP explains why 50% of Americans can't afford a healthcare emergency, how CVS is becoming a platform to solve structural healthcare problems, and why the future depends on consumers finally controlling their own health data. Timecodes: 0:00 The Healthcare Market Isn't Functioning 2:30 Consumers Don't Manage Health, They Just Expect It 3:39 Why Consumer Playbooks Die in Healthcare 5:41 Motion vs Progress: The Innovation Illusion 8:46 Platform Philosophy: "It Takes a Village" 11:38 The Vaccine Paradox Under One Roof 19:37 The 40% Hidden Reality: Healthcare Is Caregiving 21:04 The Deductible Comprehension Crisis 22:10 "This Does Have an Expiration Date" 24:40 The Health Passport Future Resources: Find Josh on LinkedIn: https://www.linkedin.com/in/joshweiner2/ Follow Julie on X: https://x.com/julesyoo Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends! a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures. Hosted by Simplecast, an AdsWizz company.

For the first time in human history, we can diagnose thousands of genetic diseases—often for under $1,000—but we still can't treat most of them. The problem isn't understanding what's broken; it's delivering the fix to the right cells. Eric Kelsic, CEO of Dyno Therapeutics, joins a16z's Jorge Conde to explain how AI-designed protein shells are solving gene therapy's delivery crisis. They explore why Huntington's patients can now get 15 extra years of healthy life, how Dyno inverted the liver-to-brain delivery ratio by 1000x, and why capsids evolved by nature are now being designed by machine learning models trained on millions of variants. Eric introduces the concept of genetic agency—humanity's first-ever ability to take action at the DNA level—and details why solving delivery for common diseases will make ultra-rare disease treatments economically viable. Plus: what happens when gene therapy requires neurosurgery today but could be a simple injection tomorrow, why recent deaths in clinical trials prove we need better technology now, and how genetic medicine could become as routine as surgery within our lifetimes. Resources: Follow Eric on X: https://x.com/ekelsic Follow Jorge on X: https://x.com/JorgeCondeBio Learn more about GATC 2025: https://www.dynotx.com/gatc2025 Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends! a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures. Hosted by Simplecast, an AdsWizz company.

Cancer care in the U.S. costs over $250 billion each year, and nearly 2 million Americans receive a new diagnosis annually, yet too often the journey begins with silence: no call, no plan, no guide. In this episode, a16z’s Vineeta Agarwala and Jay Rughani talk with Thyme Care leaders Robin Shah (cofounder and CEO), Bobby Green, MD (president and CMO), and Brad Diephuis, MD (president and COO) about rebuilding oncology around the patient. They cover where the system breaks, how navigation plus value-based contracts align incentives, how AI can extend clinicians, and what scale looks like today, more than 83,000 active patients. A concise blueprint for truly patient-centered cancer care. Timecodes: 0:00 Introduction 1:47 Personal Stories & Early Days of Time Care 5:27 Building the Team & Mission 7:07 The Patient Journey: Where the System Fails 9:58 Why Tech Hasn’t Solved Cancer Care (Yet) 15:45 Scaling Impact: Growth & Partnerships 17:45 How Time Care Works: Value-Based Care Explained 23:15 Technology, AI, and the Human Touch 37:06 Building for the Future: Generational Impact Resources: Find Robin on LinkedIn: https://www.linkedin.com/in/robin-shah-8072bb35 Find Bobby on LinkedIn: https://www.linkedin.com/in/drbobbygreen/ FInd Brad on LinkedIn: https://www.linkedin.com/in/bdiephuis/ Find Vineeta on X: https://x.com/vintweeta Find Jay on X: https://x.com/JayRughani Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends! a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures. Hosted by Simplecast, an AdsWizz company.

In this episode, Julie Yoo and Jay Rughani are joined by Thatch cofounders Chris Ellis and Adam Stevenson to explore why ICHRA—a more recent policy innovation—might quietly revolutionize employer-sponsored health benefits. Unpacking the surprising history of how U.S. healthcare became entangled with employment, they make the case for a defined-contribution future that mirrors the rise of the 401(k) and HSA. Tailored especially for today’s distributed and fast-moving workforce, ICHRA allows employers to offer tax-free health dollars employees can spend how—and where—they choose. For healthcare entrepreneurs, the conversation provides a blueprint for navigating a rapidly shifting payer landscape, including insight into how fintech infrastructure, policy tailwinds, and carrier ecosystem integrations unlock market readiness. This episode was originally published in October of 2024. The conversation remains relevant today. Hosted by Simplecast, an AdsWizz company.

In this episode, Sprinter Health co-founders Max Cohen and Cameron Behar sit down with Julie Yoo to unpack how their home-based care model reaches underserved populations and reintegrates “the unengaged” into the healthcare system. From starting with blood draws in living rooms to scaling a high-complexity, tech-enabled logistics platform, they share how operations, empathy, and human connection power their success. The duo reflects on the constraints and regulatory nuance of healthcare, revealing how humility, intentional culture-building, and pragmatism give tech-native founders an edge. Listeners will walk away with tactical advice on balancing scrappiness with long-term scalability, architecting tech-clinical collaboration, and applying AI to augment—not replace—human-delivered care. For healthcare entrepreneurs navigating systems transformation without deep domain roots, this candid conversation is both roadmap and reality check. Learn more about a16z Bio+Health Learn more about & Subscribe to Raising Health Find a16z Bio+Health on LinkedIn Find a16z Bio+Health on X Hosted by Simplecast, an AdsWizz company.

In this episode, Tennr cofounder and CEO Trey Holterman sits down with a16z’s David Haber and Jay Rughani to unpack one of healthcare’s most overlooked pain points: patient referral logistics. When a patient is referred to a specialist and told that the specialist will follow up with them, what happens next? A convoluted system sometimes involving dozens of staff and multiple portals, all of which may or may not result in the specialist actually following up. Trey shares how Tennr leverages AI to automate the complex, unstructured workflows that delay patient care and burden frontline staff. Tennr's goal is to meaningfully increase patient conversions—ensuring more people get the treatment they need, faster. Learn more about a16z Bio+Health Learn more about & Subscribe to Raising Health Find a16z Bio+Health on LinkedIn Find a16z Bio+Health on X Hosted by Simplecast, an AdsWizz company.

What if one of healthcare’s most complex administrative challenges—revenue cycle management—was reframed as a data science problem? In this episode, Malinka Walaliyadde, cofounder and CEO of AKASA, joins Julie Yoo to unpack how large language models have the potential to transform hospital revenue by automating highly nuanced coding and billing workflows. Malinka discusses how AI is finally making it possible to extract simplicity from a sea of clinical complexity and unstructured data, simplifying the flow of dollars through the healthcare system and freeing staff to focus on patients. Plus: Learn more about a16z Bio+Health Learn more about & Subscribe to Raising Health Find a16z Bio+Health on LinkedIn Find a16z Bio+Health on X Hosted by Simplecast, an AdsWizz company.

What if we stopped trying to cure disease and started preventing it instead? In this episode, Eric Topol, founder and director of the Scripps Research Translational Institute and a cardiologist, scientist, and author, joins a16z general partner Vijay Pande to unpack the future of aging, prevention, and precision health—as explored in Eric's new book, Super Agers: An Evidence-Based Approach to Longevity. Together, they discuss AI-driven risk prediction and next-gen immunotherapies — a roadmap for how we could eliminate age-related diseases before they begin. From the transformative potential of GLP-1 drugs to organ-specific aging clocks, this episode is about the innovations with the potential to expand healthspan, not just lifespan. Learn more about a16z Bio+Health Learn more about & Subscribe to Raising Health Find a16z Bio+Health on LinkedIn Find a16z Bio+Health on X Hosted by Simplecast, an AdsWizz company.

Arif Nathoo, cofounder and CEO of Komodo Health, joins Jorge Conde and Jay Rughani to explore the transformative potential of healthcare data in reshaping biotech and healthcare innovation. Arif reflects on a decade-long journey of unlocking the power of fragmented healthcare data, delving into Komodo Health’s “full-stack thesis” — a strategy that combines rich datasets, advanced analytics, and AI to enable life sciences companies, payors, and providers to make better decisions at scale. Together, the three also discuss leveraging predictive AI to identify undiagnosed patients and optimize care delivery. Arif also shares actionable advice for founders, from picking the right partner to staying steadfast in the vision. Plus: Learn more about a16z Bio+Health Learn more about & Subscribe to Raising Health Find a16z Bio+Health on LinkedIn Find a16z Bio+Health on X Hosted by Simplecast, an AdsWizz company.